XORTX to Present at Microcap Conference

Rhea-AI Summary

XORTX Therapeutics (NASDAQ: XRTX) has announced its participation and presentation at the Microcap Conference in Atlantic City, NJ, from January 28-30, 2025. The company will present on January 29, focusing on two key programs: the XRx-026 program for gout and its planned New Drug Application (NDA) filing, along with updates on the XRx-008 program for autosomal dominant polycystic kidney disease (ADPKD) and its registration clinical trial preparations.

CEO Dr. Allen Davidoff highlighted that the conference will provide opportunities for one-on-one meetings with new investors and allow the company to present its overview to conference attendees. The presentation will be recorded and made available on the company's website post-conference.

CALGARY, Alberta, Jan. 29, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANUA), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease and gout, announces attendance and presentation at the Microcap Conference hosted by DealFlow Events on January 28 through 30, 2025 in Atlantic City, NJ. Attendance at this conference continues outreach to the investment community and provides XORTX with an opportunity to update investors on our newly announced gout program. The presentation on January 29, 2025 will review the Company's plans to advance the XRx-026 program for gout through a New Drug Application (“NDA”) filing, and activities associated with the XRx-008 program for autosomal dominant polycystic kidney disease (“ADPKD”), including registration clinical trial preparations.  

Dr. Allen Davidoff, XORTX CEO stated, “This conference is designed to give participants one-on-one meetings with new investors as well as the opportunity to present a Company overview to all of the conference attendees.  We are excited to be able to reach out to the quality investors who will attend this conference and to elaborate on our exciting plans for bringing our gout program in the near term, and ADPKD programs in the longer term, through to FDA marketing approval.”

XORTX’s presentation will be recorded and available after the conference on the Company’s website.

About XORTX Therapeutics Inc.

XORTX is a pharmaceutical company with three clinically advanced products in development: 1) our lead, XRx-008 program for ADPKD; 2) our XRx-026 program for the treatment of allopurinol intolerant gout; and 3) our secondary program in XRx-101 for acute kidney and other acute organ injury associated with Coronavirus / COVID-19 infection. In addition, XRx-225 is a pre-clinical stage program for Type 2 Diabetic Nephropathy. XORTX is working to advance its clinical development stage products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. At XORTX, we are dedicated to developing medications to improve the quality of life and health of kidney disease patients and individuals with gout. Additional information on XORTX is available at www.xortx.com.

For more information, please contact:
Allen Davidoff, CEO	Nick Rigopulos, Director of Communications
adavidoff@xortx.com or +1 403 455 7727	nick@alpineequityadv.com or +1 617 901 0785

Neither the TSX Venture Exchange nor Nasdaq has approved or disapproved the contents of this news release. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.

Forward Looking Statements

This press release may contain express or implied forward-looking statements pursuant to Canadian and U.S. Federal securities laws. These forward-looking statements and their implications are based on the current reasonable expectations of the management of XORTX only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in such forward-looking statements. Except as otherwise required by law, XORTX undertakes no obligation to publicly release any revisions or updates to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting XORTX is contained in the Company’s most recently filed Annual Information Form and the Management Discussion and Analysis for its most recent financial reporting period filed on the Company’s SEDAR profile (www.sedar.com) and under the heading “Risk Factors” in XORTX’s Registration Statement on Form F-1 filed with the Securities and Exchange Commission (“SEC”) available on the SEC's website, www.sec.gov.

FAQ

What will XORTX present at the 2025 Microcap Conference?

XORTX will present updates on their XRx-026 gout program's NDA filing plans and the XRx-008 program for ADPKD, including clinical trial preparations, on January 29, 2025.

When and where is XORTX presenting at the Microcap Conference?

XORTX is presenting on January 29, 2025, at the Microcap Conference hosted by DealFlow Events in Atlantic City, NJ, which runs from January 28-30, 2025.

What are the two main drug programs XRTX is developing?

XRTX is developing XRx-026 for gout treatment and XRx-008 for autosomal dominant polycystic kidney disease (ADPKD).

How can investors access XORTX's Microcap Conference presentation?

The presentation will be recorded and made available for viewing on XORTX's company website after the conference.

What opportunities does the Microcap Conference provide for XRTX?

The conference provides XRTX with opportunities for one-on-one meetings with new investors and allows them to present their company overview to conference attendees.